Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

137.16
-0.3200-0.23%
Post-market: 137.260.1000+0.07%19:44 EDT
Volume:2.35M
Turnover:324.19M
Market Cap:261.70B
PE:20.74
High:139.55
Open:139.31
Low:137.00
Close:137.48
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:0.61
T/O Rate:0.13%
Dividend:4.67
Dividend Rate:3.40%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.30
PE(LYR):19.18

Loading ...

Novartis MS Trials Open Door to Multibillion-Dollar Sales Opportunity

Dow Jones
·
Sep 01

Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials

TIPRANKS
·
Sep 01

Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement

TradingKey
·
Sep 01

Novartis's Multiple Sclerosis Trial Results Match Best Hopes

Dow Jones
·
Sep 01

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Stock News
·
Sep 01

Novartis up Nearly 6%, on Pace for Largest Percent Increase Since March 2023

Dow Jones
·
Sep 01

Movement Alert|Novartis AG Rises 6.73% in Regular Trading, MS Oral Drug Remibrutinib Meets Primary Endpoints in Phase 3 Trials

Market Focus
·
Sep 01

Sector Update: Healthcare Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Sep 01

【US Pre-Market】US Futures and Chip Stocks Fall as Global Bond Sell-Off Deepens; Gold Drops Below $4,400, Brent Crude Tops $92

TradingKey
·
Sep 01

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

Why Novartis Stock is Heading for Its Best Day Since 2023 After 3 Patient Deaths

Dow Jones
·
Sep 01

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Dow Jones
·
Sep 01

Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib

TIPRANKS
·
Sep 01

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

TIPRANKS
·
Sep 01

Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials

MT Newswires Live
·
Sep 01

Movement Alert|Novartis AG Rises 5.22% in Pre-Market Trading, CAR-T Autoimmune Trial Halt Paired with Positive MS Oral Drug Data

Market Focus
·
Sep 01

Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise

Stock News
·
Sep 01

Movement Alert|Novartis AG Rises 5.19% Overnight, Pauses Eight Autoimmune CAR-T Clinical Trials Following Patient Deaths

Market Focus
·
Sep 01

Novartis Pauses Autoimmune Cell Therapy Studies After Deaths

Dow Jones
·
Sep 01

Novartis AG Falls Monday, Outperforms Market

Dow Jones
·
Sep 01